Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for Hard-to-Treat cancers: first human trial of TYRA-430 begins

NCT ID NCT06915753

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 27 times

Summary

This early-stage study tests a new oral drug, TYRA-430, in about 100 adults with advanced liver cancer or other solid tumors that have specific genetic changes (FGF/FGFR pathway). The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug shrinks tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Asan Medical Center

    RECRUITING

    Seoul, South Korea

  • Columbia University Irving Medical Center

    RECRUITING

    New York, New York, 10043, United States

  • John Hopkins University

    RECRUITING

    Baltimore, Maryland, 21205, United States

  • Karmanos Cancer Institute

    RECRUITING

    Detroit, Michigan, 48201, United States

  • Mass General Cancer Center

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • National Taiwan University Hospital

    RECRUITING

    Taipei, Taiwan

  • Samsung Medical Center

    RECRUITING

    Seoul, South Korea

  • Sarah Cannon Research Institute Oncology Partners

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Seoul National University Hospital

    RECRUITING

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    RECRUITING

    Seoul, South Korea

  • Stanford Cancer Institute

    RECRUITING

    Stanford, California, 94305, United States

  • Taipei Veterans General Hospital

    RECRUITING

    Taipei, Taiwan

  • The University of Kansas Medical Center

    RECRUITING

    Westwood, Kansas, 66205, United States

  • UCSF Medical Center at Mount Zion

    RECRUITING

    San Francisco, California, 94158, United States

  • USC Norris Comprehensive Cancer Center

    RECRUITING

    Los Angeles, California, 90033, United States

  • University Health Network Princess Margaret Cancer Center

    RECRUITING

    Toronto, Ontario, M5G 2C4, Canada

Conditions

Explore the condition pages connected to this study.